U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H24ClFO7.C5H9NO2
Molecular Weight 570.004
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HENAGLIFLOZIN PROLINE

SMILES

OC(=O)[C@H]1CCCN1.CCOC2=C(F)C=C(CC3=C(Cl)C=CC(=C3)[C@@]45OC[C@@](CO)(O4)[C@@H](O)[C@H](O)[C@H]5O)C=C2

InChI

InChIKey=HSHUXRQZEKRWMX-CGDHVTPMSA-N
InChI=1S/C22H24ClFO7.C5H9NO2/c1-2-29-17-6-3-12(8-16(17)24)7-13-9-14(4-5-15(13)23)22-20(28)18(26)19(27)21(10-25,31-22)11-30-22;7-5(8)4-2-1-3-6-4/h3-6,8-9,18-20,25-28H,2,7,10-11H2,1H3;4,6H,1-3H2,(H,7,8)/t18-,19-,20+,21+,22+;4-/m01/s1

HIDE SMILES / InChI

Molecular Formula C22H24ClFO7
Molecular Weight 454.873
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C5H9NO2
Molecular Weight 115.1305
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Henagliflozin (also known as SHR3824) was developed by Jiangsu HengRui Medicine as a sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. This drug successfully passed phase I clinical trials, however, information about further development is not available.

Approval Year

PubMed

PubMed

TitleDatePubMed
Evaluation of drug-drug interaction between henagliflozin, a novel sodium-glucose co-transporter 2 inhibitor, and metformin in healthy Chinese males.
2016-08
Pharmacokinetics and Pharmacodynamics of Henagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Chinese Patients with Type 2 Diabetes Mellitus.
2016-03
SHR3824, a novel selective inhibitor of renal sodium glucose cotransporter 2, exhibits antidiabetic efficacy in rodent models.
2014-05

Sample Use Guides

to evaluate the pharmacodynamics (PD), pharmacokinetics (PK), safety and tolerability following single and multiple oral doses of 5mg to 20 mg SHR3824 in Type 2 diabetes mellitus patients.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Wed Apr 02 05:51:27 GMT 2025
Edited
by admin
on Wed Apr 02 05:51:27 GMT 2025
Record UNII
4IO819SW6M
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HENAGLIFLOZIN PROLINE
Common Name English
Henagliflozin proline [WHO-DD]
Preferred Name English
Code System Code Type Description
PUBCHEM
146019519
Created by admin on Wed Apr 02 05:51:27 GMT 2025 , Edited by admin on Wed Apr 02 05:51:27 GMT 2025
PRIMARY
FDA UNII
4IO819SW6M
Created by admin on Wed Apr 02 05:51:27 GMT 2025 , Edited by admin on Wed Apr 02 05:51:27 GMT 2025
PRIMARY
SMS_ID
300000040273
Created by admin on Wed Apr 02 05:51:27 GMT 2025 , Edited by admin on Wed Apr 02 05:51:27 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY